Should You Buy vTv Therapeutics Inc (NASDAQ: VTVT) in 2021?

vTv Therapeutics Inc (NASDAQ: VTVT) is up over 55% on December 11 after investment group MacAndrews & Forbes bought about 625,000 shares of the company, worth around $1 million. vTv is a clinical-stage biopharmaceutical company whose research and development is focused on orally administered small molecule drug candidates, treatments for Alzheimer’s disease, diabetes, and inflammatory disorders. In November, the company signed a stock purchase agreement for up to $47 million with Chicago-based institutional investor Lincoln Park Capital Fund.

There are several catalysts in line for this stock, including topline results of phase 2 Elevage study of Alzheimer’s disease and type 2 diabetes patients, TTP399, the company’s oral treatment for type 1 diabetes focused on its impact on diabetic ketoacidosis.